This author has not written his bio yet.
But we are proud to say that Reuters Health contributed 4488 entries already.
Biogen Inc. and partner Eisai Co. Ltd. are ending two late-stage trials for the experimental Alzheimer’s drug aducanumab, in a setback to efforts to find treatments for the disease and for Biogen’s stock, which lost more than $17 billion of the company’s value.
Roche is seeking damages and compensation in a U.S. lawsuit against former executives of a Utah-based company, the Swiss drugmaker’s latest case targeting what the company calls fraudulent schemes involving its diabetes test strips.
The U.S. Food and Drug Administration approved Jazz Pharmaceuticals Plc’s treatment for patients with a form of sleep disorder.
The U.S. Food and Drug Administration will temporarily allow certain manufacturers to sell blood pressure medications containing specified levels of a probable cancer-causing impurity in order to maintain adequate supplies of the drug.
Novo Nordisk submitted the company’s oral semaglutide drug, a pill that management hopes will transform the diabetes market, for approval in the United States.
Pfizer acquired a 15 percent stake in Vivet Therapeutics as well as an exclusive option to fully acquire the business, a deal that will give the New York-based pharma giant access to the French company’s experimental gene therapy for a rare genetic disorder.
World Health Organization experts said it would be irresponsible for any scientist to conduct human gene-editing studies in people, and a central registry of research plans should be set up to ensure transparency,
People who consume lots of sugary sodas and sports drinks every day may be more likely to die early of causes like heart disease and cancer than people who rarely if ever indulge in these beverages, a U.S. study suggests.
Swiss drugmaker Roche Holding AG’s U.S. unit Genentech Inc. won approval for the immunotherapy Tecentriq for a tough-to-treat type of lung cancer.
The U.S. Food and Drug Administration placed a partial clinical hold on all trials of AbbVie’s Venclexta for multiple myeloma, after a review of data found a higher proportion of deaths in the cancer drug arm of the late-stage study.
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds: